BiotechTube
Home/Resoundant/Jeremiah Heilman, PhD
JH

Jeremiah Heilman, PhD

Vice President of Design and Engineering

Resoundant

Therapeutic Areas

Liver DiseasesFibrosis

Resoundant Pipeline

DrugIndicationPhase
Liver MRE for Fibrosis StagingLiver Fibrosis (MASLD, MASH, Hepatitis)Approved
MRE as a Biomarker in Clinical TrialsMASH (as a surrogate endpoint)Biomarker Qualification
MRE for Tumor CharacterizationOncology (Brain, Breast, Prostate Tumors)Pre-clinical/Research

Leadership Team at Resoundant

RL
Richard L. Ehman, MD
Chief Executive Officer
KP
Kay Pepin, PhD
Chief Operating Officer
RF
Rashid Fehmi, CPA
Chief Financial Officer
MK
Mike Kalutkiewicz, MA
Vice President of Global Policy and Communications
View full Resoundant profile